Experienced in Essential Thrombocythemia

Dr. Brenda W. Cooper

University Hospitals Medical Group, Inc.
Cleveland, OH
Experienced
in Essential Thrombocythemia
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Brenda Cooper is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Cooper and is rated as an Experienced provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Cooper is currently accepting new patients.

Her clinical research consists of co-authoring 53 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Uh Cleveland Medical Center
University Hospitals Portage Medical Center
University Hospitals Ahuja Medical Center
Parma Community General Hospital
Lake Health
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Aetna
  •  Anthem
  •  Ambetter
  •  Medical Health
  •  CareSource
  •  Humana

Locations

UNIVERSITY HOSPITALS MEDICAL GROUP INC
11100 Euclid Ave, Cleveland, OH 44106
216-896-1755
Other Locations
UNIVERSITY HOSPITALS MEDICAL GROUP INC
3909 Orange Pl, Suite 1100, Beachwood, OH 44122
216-896-1755

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: January 15, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: February 22, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 17, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 11 Less Clinical Trials

55 Total Publications

Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 13, 2024
Similar Doctors
Expertise in
21
conditions
Dr. Aaron T. Gerds
Hematology Oncology | Hematology | Oncology
Expertise in
21
conditions
Dr. Aaron T. Gerds
Hematology Oncology | Hematology | Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.9 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Aaron Gerds is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Gerds and is rated as an Elite provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
72
conditions
Dr. Richard Y. Chang
Hematology Oncology | Hematology | Oncology
Expertise in
72
conditions
Dr. Richard Y. Chang
Hematology Oncology | Hematology | Oncology

University Primary Care Practices Inc

29325 Health Campus Dr, Suite 1, 
Westlake, OH 
 (18.2 mi)
440-617-4700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Richard Chang is a Hematologist Oncology specialist and a Hematologist in Westlake, Ohio. Dr. Chang and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Lynch Syndrome, Colorectal Cancer, Familial Colorectal Cancer, and Lung Adenocarcinoma. Dr. Chang is currently accepting new patients.

Expertise in
12
conditions
Dr. Yiping L. Wang
Hematology Oncology | Oncology | Hematology
Expertise in
12
conditions
Dr. Yiping L. Wang
Hematology Oncology | Oncology | Hematology

Summa Physicians Inc

161 N Forge St, Suite 190, 
Akron, OH 
 (29.9 mi)
330-375-3557
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Yiping Wang is a Hematologist Oncology specialist and an Oncologist in Akron, Ohio. Dr. Wang and is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Paget Disease of the Breast, Essential Thrombocythemia, and Multiple Myeloma. Dr. Wang is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile